Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Topical Rapamycin to Erase Angiofibromas in TSC-Multicenter Evaluation of a Novel Therapy

NCT01526356 is registered in ClinicalTrials.gov with The University of Texas Health Science Center, Houston as lead sponsor.

NCT NCT01526356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01526356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Topical Rapamycin to Erase Angiofibromas in TSC-Multicenter Evaluation of a Novel Therapy
Lead sponsor
The University of Texas Health Science Center, Houston
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
August 31, 2014
Enrollment
179 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

angiofibromas, tuberous sclerosis